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Abstract: Lung cancer is the most common cause of cancer deaths. 
Most patients present with advanced-stage disease, and the prognosis 
is generally poor. However, with the understanding of lung cancer biol-
ogy, and development of molecular targeted agents, there have been 
improvements in treatment outcomes for selected subsets of patients 
with non–small-cell lung cancer (NSCLC). Epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated 
significantly improved tumor responses and progression-free survival 
in subsets of patients with advanced NSCLC, particularly those with 
tumors harboring activating EGFR mutations. Testing for EGFR 
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mutations is a standard procedure for identification of patients who 
will benefit from first-line EGFR TKIs. For patients with advanced 
NSCLC and no activating EGFR mutations (EGFR wild-type) or no 
other driving oncogenes such as ALK-gene rearrangement, chemo-
therapy is still the standard of care. A new generation of EGFR TKIs, 
targeting multiple receptors and with irreversible bindings to the 
receptors, are in clinical trials and have shown encouraging effects. 
Research on primary and acquired resistant mechanisms to EGFR 
TKIs are ongoing. Monoclonal antibodies (e.g. cetuximab), in com-
bination with chemotherapy, have demonstrated improved outcomes, 
particularly for subsets of NSCLC patients, but further validations are 
needed. Novel monoclonal antibodies are combined with chemother-
apy, and randomized comparative studies are ongoing. This review 
summarizes the current status of EGFR inhibitors in NSCLC in 2012 
and some of the major challenges we are facing.
Key Words: EGFR antibodies, Carcinoma, non–small-cell lung, 
Molecular targeted therapy, Epidermal growth factor receptor, 
Tyrosine kinase inhibitors
(J Thorac Oncol. 2013;8: 373-384)
Recently, molecularly targeted agents have shown impres-sive activity in terms of response and clinical outcome 
for subgroups of patients with non–small-cell lung cancer 
(NSCLC). Epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs) were the first targeted agents to dem-
onstrate significantly improved responses and outcomes in 
patients with advanced NSCLC, first as second- and third-line 
therapy,1 and later, in the first-line2 and maintenance settings.3
New generations of EGFR TKIs (i.e. afatinib, dacomi-
tinib), targeting several ErbB family receptors and with irre-
versible binding to the receptors, are being developed, and 
have demonstrated encouraging clinical effects. However, 
almost all patients develop resistance eventually and much 
research is focusing on identifying and circumventing pri-
mary and acquired resistance.
Monoclonal antibodies (e.g. cetuximab) in combination 
with chemotherapy have demonstrated marginal survival ben-
efit, which is more significant in highly selected subgroups, 
although, this needs further validation. Newer antibodies are 
currently in clinical trials. Although we are making rapid 
progress with therapy with EGFR inhibitors, many questions 
are yet to be answered.
An EGFR summit was held in 2011 to discuss and 
summarize the status of EGFR inhibitors in NSCLC, which 
formed the basis for this report. The information has been 
updated and includes the latest developments in 2012, and 
also describes some of the major challenges we are facing 
to optimize treatment for patients with EGFR oncogenic-
addicted NSCLC tumors.
EGFR InhIbItIon as FIRst-LInE thERapy
Seven randomized studies confirmed the role of first-
line reversible EGFR TKIs in patients with activating EGFR 
mutations (Table 1).2,4–8,14 The Iressa Pan-Asia Study (IPASS), 
a multinational, multicenter trial, compared first-line gefitinib 
with paclitaxel or carboplatin in 1217 never or light Asian 
smokers, with adenocarcinoma.2 Activating EGFR mutations 
were found in 60% of 437 patients tested, and both objec-
tive response rate (ORR) and progression-free survival (PFS) 
favored single-agent gefitinib in this subgroup. Similar find-
ings were noted in a Korean study that also selected patients 
by clinical parameters,4 and four other studies that selected 
patients by molecular biomarkers.5–8 These studies consis-
tently demonstrated significant improvements in PFS for 
EGFR therapy alone, and toxicities, particularly neutropenia, 
thrombocytopenia, and neuropathy, that were lesser in patients 
treated with EGFR TKIs. Seven patients had fatal interstitial 
lung disease (incidence 0.0 to 5.3%). IPASS also reported 
improved quality of life in patients with EGFR mutation 
treated with gefitinib.2 There were no significant differences 
in overall survival (OS) between the treatment arms, probably 
because of crossover from chemotherapy to EGFR TKI at dis-
ease progression. These studies confirm that clinical charac-
teristics are not sufficient for selection of patient for first-line 
EGFR TKIs..2,4
Five of the seven phase III studies were only conducted 
on Asian populations,2,4–7 and only the European Tarceva (erlo-
tinib) versus Chemotherapy (EURTAC) study was conducted 
in a white population.8 This raised the question of whether 
the high efficacy of EGFR TKIs is unique to Asian patients. 
However, two single-arm studies from Spain9 and the United 
States,10 on patients with known EGFR mutations, reported 
response rates of 71% and 55%, and PFS of 14 months and 
11.4 months, respectively. In EURTAC, the ORR to first-line 
erlotinib was 54.5% and PFS was 9.4 months.8 These results 
suggest that, although, the incidence of activating EGFR muta-
tions is less in whites,10 there are no significant differences in 
treatment outcomes between patients with EGFR mutation of 
different ethnicity.
In contrast to the first-generation EGFR TKIs, the 
second-generation irreversible EGFR TKIs have the benefit 
of forming covalent, and therefore, permanent bonds with the 
target, which should increase their effectiveness by prolonging 
the inhibition of EGFR signaling to the entire lifespan of the 
drug-bond receptor molecule. In vitro studies demonstrated 
that irreversible binding of TKIs effectively killed cells that 
had acquired resistance to first-generation TKIs.11 The second-
generation irreversible EGFR TKIs were also designed to target 
additional ErbB-family member receptors, such as HER-2 or 
other downstream or parallel pathways. Dacomitinib, a pan-
HER inhibitor, was studied in a single-arm phase II study 
in a population enriched for EGFR mutation.12 The tumor 
response rate was 74% and PFS was 17 months. Afatinib, 
an EGFR or HER2 or HER3 inhibitor, is another irreversible 
TKI that was studied in both phase II and III studies. Yang 
et al.13 reported a response rate of 66% in 106 patients with 
the common EGFR mutations and PFS was 13.7 months. The 
LUX-Lung 3 randomized phase III study compared afatinib 
with chemotherapy (cisplatin/pemetrexed) in NSCLC patients 
with EGFR mutations and included both Asians and whites.14 
A significant PFS benefit with concomitant symptomatic 
improvement was seen with afatinib (median PFS, 11.0 versus 
6.9 months; HR = 0.58). For patients with the common EGFR 
mutations at exon 19 and 21, PFS was 13.6 months. However, 
afatinib did not show particularly great effect in patients 
with tumors harboring rare EGFR mutations or having the 
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T790M-resistant mutation.14 Approval of afatinib as first-line 
therapy for advanced NSCLC in patients with EGFR mutations 
are currently under evaluation. Both dacomitinib and afatinib 
were associated with higher incidences of diarrhea, skin rash, 
and stomatitis than first-generation EGFR TKIs.
The question is whether the different EGFR TKIs have 
different efficacy and toxicity as first-line therapy for patients 
with activating EGFR mutations. To date, only one small, 
underpowered randomized study from Korea has compared 
gefitinib with erlotinib in clinically-selected lung cancer 
patients who had previously failed chemotherapy. No signifi-
cant difference between the two drugs was observed.15 A com-
parative study of these EGFR TKIs would require a sample 
size of approximately 1000 patients with EGFR mutations to 
show superiority, and is unlikely to be performed. A pooled 
analysis of retrospective and prospective studies that evaluated 
treatment outcomes of chemotherapy, gefitinib, or erlotinib in 
patients with EGFR mutations reported median PFS of 5.9, 
9.8, and 13.2 months, respectively.16 However, PFS of patients 
receiving first-line erlotinib was 9.4 months in the EURTAC 
study,8 which is similar to the results of studies of gefitinib. 
Afatinib and dacomitinib seem to be associated with longer 
PFS. A multinational, randomized phase IIb study comparing 
afatinib with gefitinib (LUX Lung-7) is ongoing. All enrolled 
patients must have activating EGFR mutations (Del 19 or 
L858R) and the primary end point is PFS.
Four randomized studies addressed the question of com-
bining chemotherapy with EGFR TKI in unselected advanced 
NSCLC patients. Concurrent administration of chemotherapy 
and EGFR TKIs improved neither response nor survival in 
several randomized trials.17–20 However, treatment effects may 
potentially be improved by pharmacodynamic separation of 
the chemotherapy and EGFR TKI.21 A randomized study com-
pared erlotinib alone to chemotherapy intercalated with erlo-
tinib.22 The intercalated approach had a higher response rate 
(22.4% versus 11.6%) and longer median PFS (4.6 versus 2.7 
months), but no OS difference. The first-line Asian Sequential 
Tarceva And Chemotherapy Trial was a placebo-controlled, 
randomized, phase II study of 150 unselected patients given 
gemcitabine (G) and carboplatin (C) on days 1 and 8, followed 
by erlotinib on days 15 to 28.23 All patients received erlotinib 
or placebo as maintenance therapy. Response rates were 37% 
versus 24% favoring the sequential erlotinib arm. Median PFS 
was 7.2 months with erlotinib versus 5.5 months with placebo 
(HR = 0.47). A randomized, phase III study (first-line Asian 
Sequential Tarceva and Chemotherapy Trial II) of 451 Asian 
patients was completed and confirmed a significant difference 
in PFS favoring the G-C-erlotinib combination over G-C-
placebo (median PFS, 7.6 months versus 6.0 months; HR = 
0.57). The ORR was also better with G-C-erlotinib treatment 
(43% versus 18%).24
Exploratory subset analysis of the TRIBUTE study 
(chemotherapy ± erlotinib as first-line therapy in all patients 
with advanced NSCLC) revealed that the addition of erlotinib 
to chemotherapy prolonged OS in patients who had never 
smoked (median OS, 22.5 versus 10.1 months).19 This obser-
vation led to the Cancer and Leukemia Group B (CALGB-
30406) phase II study of 181 patients with stage IIIB and IV 
adenocarcinoma who were never or light smokers.25 Patients 
were randomized to erlotinib monotherapy or erlotinib plus 
carboplatin and paclitaxel followed by erlotinib, and this study 
showed that chemotherapy failed to improve on the outcome 
of erlotinib alone in this selected group of patients. To date, 
there is sufficient evidence to conclude that clinical trials of 
EGFR TKI need to be supported by biomarker analysis.
EGFR-directed monoclonal antibodies that have 
been evaluated in patients with NSCLC include cetuximab, 
matuzumab, panitumumab, nimotuzumab, and necitumumab.26 
Cetuximab was studied in two phase III trials of advanced 
NSCLC.27,28 The First-Line Erbitux in Lung Cancer (FLEX) 
tabLE 1.  Randomized Studies Comparing EGFR TKI with Chemotherapy in Patients with EGFR Mutation
Author Study EGFR TKI No. of Patients
Tumor Response 
Rate (%)
Median PFSa (Mo) HR 
(95% CI)
Median OSa (Mo) HR  
(95% CI)
Mok et al.2 IPASS Gefitinib 261 71.2 vs. 47.3 9.8 vs. 6.4 HR = 0.48  
(0.36–0.64, p < 0.001)
21.6 vs. 21.9 HR = 1.00  
(0.76–1.33, p = 0.99)
Han et al.4 First-SIGNAL Gefitinib 42 84.6 vs. 37.5 8.4 vs. 6.7 HR = 0.61  
(0.308–1.221, p = 0.084)
30.6 vs. 26.5 HR = 0.823 
(0.352–1.922, p = 0.65)
Mitsudomi et al.5 WJTOG 3405 Gefitinib 172 62.1 vs. 32.2 9.6 vs. 6.6 HR = 0.52  
(0.38–0.72, p < 0.0001)
35.5 vs. 38.8 HR = 1.18  
(0.77–1.83)
Maemondo et al.6 NEJ002 Gefitinib 228 73.7 vs. 30.7 10.8 vs. 5.4 HR = 0.32  
(0.24–0.44, p < 0.001)
27.7 vs. 26.6 HR = 0.88  
(0.63–1.24, p = 0.31)
Zhou et al.7 OPTIMAL Erlotinib 154 83.0 vs. 36.0 13.7 vs. 4.6 HR = 0.16  
(0.11–0.26, p < 0.0001)
22.7 vs. 28.9 HR = 1.04  
(0.69–1.58)
Rosell et al.8 EURTAC Erlotinib 173 58.1 vs. 14.9 9.7 vs. 5.2 HR = 0.37  
(0.25–0.54, p < 0.0001)
19.3 vs. 19.5 HR = 1.04  
(0.65–1.68)
Yang et al.14 LUX-Lung 3 Afatinib 345 56.1 vs. 22.6b 11.1 vs. 6.9 HR = 0.59  
(0.43–0.78, p = 0.0004)
aEGFR TKI vs. chemotherapy.
bLUX-Lung 3: response by independent review.
IPASS, Iressa Pan-Asia Study; First-SIGNAL, first-line single agent Iressa versus Gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung; 
WJTOG, West Japan Thoracic Oncology Group; NEJ, North East Japan; OPTIMAL, Randomised phase III study comparing first-line erlotinib versus carboplatin plus 
gemcitabine in Chinese advanced non–small-cell lung cancer patients with EGFR-activating mutations; EURTAC, European Tarceva (erlotinib) vs. chemotherapy. EGFR TKI, 
epidermal growth factor receptor tyrosine kinase inhibitor; HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; OS, overall survival.
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trial in patients with EGFR-positive tumors demonstrated a 
marginal survival benefit for cetuximab added to cisplatin and 
vinorelbine compared with chemotherapy alone (median OS, 
11.3 versus 10.1 months; HR = 0.87; p = 0.04).27 However, 
the Bristol Myers Squibb 099 (BMS-099) study in unselected 
NSCLC patients failed to demonstrate longer PFS (primary 
end point) for cetuximab with carboplatin and taxane, although 
the HR for OS was similar to that of FLEX.28,29 Patients who 
developed early-onset rash in the FLEX study (within 3 weeks) 
had longer survival than those without rash.30 EGFR gene copy 
number assessed by fluorescence in situ hybridization (FISH) and 
Kirsten rat sarcoma (KRAS), and EGFR mutation status did not 
predict clinical outcome in either phase III trial.31,32 However, a 
semiquantitative assessment of EGFR protein expression based 
on a histo-score (H-score) of 200 or more predicted treatment 
outcomes in FLEX (HR = 0.73; 95% confidence interval [CI], 
0.58–0.93; median OS, 12.0 [H-score, ≥200] versus median 
OS, 9.6 months [H-score <200]).33 In a phase II study by the 
Southwest Oncology Group (SWOG-0342), EGFR FISH-
positive patients had significantly higher response rates and 
longer survival after chemotherapy plus cetuximab than EGFR 
FISH-negative patients.34 Both the EGFR protein H-score and 
EGFR FISH copy number are being validated prospectively in 
a large phase III study (SWOG-0819).
Necitumumab, a fully human monoclonal antibody, is 
being evaluated in phase III trials in combination with cis-
platin and pemetrexed in advanced nonsquamous NSCLC 
(INSPIRE study) and with cisplatin and gemcitabine in 
patients with advanced squamous lung cancer (SQUIRE 
study). However, the INSPIRE study was prematurely stopped 
after enrolling approximately 600 patients because of toxic-
ity that was higher than expected in the experimental arm 
(data expected to be released in 2013). The SQUIRE study 
is fully enrolled (approximately 1100 patients). Matuzumab 
and panitumumab have been studied only in phase II trials 
in advanced NSCLC.35,36 Nimotuzumab, a 95% human EGFR 
antibody with supposedly less skin and gastrointestinal toxic-
ity compared with other EGFR antibodies has been mainly 
investigated in phase I and II studies in Asia.
MaIntEnancE thERapy FoR nscLc
Maintenance therapy, defined as treatment for patients 
who do not have disease progression after four to six cycles 
of first-line chemotherapy, has been studied extensively 
(Table 2).3,37–44 Maintenance therapy may use the same agent 
that was given as first-line chemotherapy (continuation main-
tenance) or introduce a different drug (switch maintenance). 
Five trials evaluated the role of switch maintenance with 
EGFR TKIs.3,40–42,44 In the West Japan Thoracic Oncology 
Group study, 604 patients with advanced NSCLC were ran-
domized to receive platinum-doublet chemotherapy for six 
cycles or platinum-doublet chemotherapy for three cycles fol-
lowed by gefitinib. There was significant improvement in PFS 
(HR = 0.68; p = 0.001), but not OS (HR = 0.86; p = 0.11) 
with maintenance gefitinib. However, there was a significant 
OS benefit in patients with adenocarcinoma.42 The phase III 
Sequential Tarceva in Unresectable NSCLC (SATURN) study 
randomized 889 patients who did not progress after four 
cycles of first-line chemotherapy to receive maintenance erlo-
tinib or placebo.3 Patients receiving erlotinib had significantly 
longer PFS and OS. The OS improvement was observed only 
in the EGFR wild-type population and not in the patients with 
EGFR mutations, probably because of the confounding effect 
of the crossover treatment and the limited number of patients 
with EGFR mutations. The Adjuvant Tarceva Longer Against 
Shorter (ATLAS) phase III trial randomly assigned stable and 
responding patients after four cycles of platinum-based che-
motherapy plus bevacizumab to continue bevacizumab alone 
or with erlotinib.40 Similar to SATURN, the highest PFS ben-
efit was observed in the EGFR mutation population. Recently, 
Chinese investigators reported the results of INFORM, a phase 
III trial comparing maintenance gefitinib versus placebo after 
first-line platinum-based chemotherapy.44 Although PFS was 
significantly prolonged, there was no difference in OS. Again 
the most significant benefits were observed in patients with 
activating EGFR mutations.
Treatment response to front-line chemotherapy may also 
effect the efficacy of maintenance EGFR TKI. In SATURN 
and The Adjuvant Tarceva Longer Against Shorter studies, the 
survival benefit produced by erlotinib was confined to patients 
with stable disease, with no difference in patients with partial 
response to first-line chemotherapy.40,45 A different scenario 
emerged in trials of continuation maintenance therapy. In the 
PARAMOUNT trial, maintenance pemetrexed produced a 
survival benefit irrespective of response to front-line therapy.43
Recent phase III trials show that, irrespective of the 
maintenance agent used, a treatment started immediately 
after four to six cycles of platinum-based chemotherapy, 
can prolong PFS, and potentially OS. Erlotinib, pemetrexed, 
or docetaxel given as maintenance therapy may not be bet-
ter than the same agents given as second-line treatment, but 
maintenance therapy offers the possibility of treating all sta-
ble and responding patients, and reducing the proportion of 
patients who are unfit for treatment at the time of progression. 
Decisions concerning the use of maintenance therapy should 
be tailored according to patient preference, response to previ-
ous therapy, EGFR status, histology, and performance status.
sEcond-LInE thERapy
The chemotherapy agents docetaxel and pemetrexed are 
approved for second-line treatment of advanced NSCLC.46-48 
In addition, the EGFR TKIs, erlotinib and gefitinib, are 
approved. Gefitinib is available in Asia as second-line therapy, 
and in Europe only for patients with EGFR mutations. Erlotinib 
was approved for the second- and third-line treatment of 
advanced NSCLC based on the National Cancer Institute of 
Canada Clinical Trials Group BR.21 study, which included 731 
previously-treated patients with advanced NSCLC randomized 
to receive erlotinib or placebo. OS improved in erlotinib-treated 
patients (6.7 versus 4.7 months; p = 0.001).1 Gefitinib was 
approved conditionally based on two phase II trials (Iressa Dose 
Evaluation for Advanced Lung Cancer 1 and 2) that showed 
response rates of 10% to 19%.49,50 However, a phase III study, 
Iressa Survival Evaluation in Lung Cancer (ISEL), a placebo-
controlled, randomized trial with more than 1600 previously-
treated patients, reported no significant OS improvement with 
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gefitinib over placebo.51 On the basis of the ISEL results, the 
U.S. Food and Drug Administration withdrew approval for 
new patients to start gefitinib. Application to the European 
authority for use of the drug in unselected populations was 
withdrawn. In Japan, gefitinib was approved in 2002. Although, 
the ISEL study failed to show a survival advantage of gefitinib 
over placebo (p = 0.087), subset analysis revealed a gefitinib 
advantage in patients with Asian ethnicity (p = 0.01), most 
likely because of enrichment for EGFR mutations. Because of 
this analysis, and the fact that erlotinib was not available at that 
time in Japan, gefitinib continues to be a second-line treatment 
option in Japan.
The role of EGFR TKIs as second- and third-line therapy 
for patients with EGFR wild-type tumors remains controversial. 
The Iressa non–small-cell lung cancer Trial Evaluating Response 
and Survival against Taxotere (INTEREST) compared gefitinib 
to docetaxel in 1433 patients with advanced NSCLC, who had 
received platinum-based chemotherapy.52 The study demon-
strated noninferiority of gefitinib compared with docetaxel for 
OS (7.6 versus 8.0 months; HR = 1.02; 95% CI, 0.91–1.15). 
Subgroup analysis of EGFR wild-type patients in BR.21 reported 
an HR of 0.74 (p = 0.09). A recent randomized trial comparing 
erlotinib with docetaxel (Tarceva Italian Lung Optimization Trial 
[TAILOR] study) for patients with EGFR wild-type tumors after 
previous chemotherapy reported longer PFS favoring chemother-
apy (median PFS, 3.4 months versus 2.4 months; HR = 0.69).53 
However, this is only a secondary study end point, whereas the 
primary end point of overall survival is not mature.
A recent randomized, phase II study has compared 
dacomitinib to erlotinib as second- and third-line therapy for 
patients with advanced NSCLC.54 Dacomitinib demonstrated 
significantly improved PFS versus erlotinib in most clinical 
subsets, notably in patients with KRAS wild-type tumors and 
in patients with activating EGFR mutations. A randomized 
phase III study comparing the two EGFR TKIs is ongoing.
EaRLy and LocaLLy advancEd nscLc
Treatment of early-stage NSCLC potentially includes 
surgery and radiation with or without chemotherapy. With 
these approaches, cure can be achieved in approximately 
55% of stage I patients, 40% of stage II, and 20% to 30% of 
stage III, which leaves considerable room for improvement.55 
Currently, there is no established role for EGFR-targeting 
drugs as postoperative treatment (demonstrated by the NCIC 
BR.19 trial) or as maintenance therapy in stage III NSCLC 
(Table 3).56–59 Chemotherapy should be offered as adjuvant 
therapy in patients with stages II and IIIA. A large random-
ized trial of postoperative adjuvant erlotinib versus placebo 
(Randomized Double-blind Trial in Adjuvant NSCLC with 
Tarceva [RADIANT]) has finished accrual. This trial required 
tumor expression of EGFR protein or high EGFR copy, and 
samples were available from all the participants. Studies of 
EGFR and KRAS mutation, circulating DNA, EGFR ligands, 
and other potential markers will also be performed. This sen-
tinel study will determine further development of EGFR-
directed therapy in the adjuvant setting.59 Two randomized 
studies comparing gefitinib with adjuvant chemotherapy in 
patients with surgically resected EGFR mutation-positive 
adenocarcinoma are ongoing in Japan and China.
A randomized trial in stage III NSCLC investigated 
gefitinib versus placebo consolidation therapy in an unselected 
population after chemoradiotherapy (SWOG-0023).57 The 
trial was terminated prematurely after randomization of 243 
patients when the negative results of ISEL were published. 
Patients on maintenance gefitinib had significantly worse 
survival than those on placebo. The reasons for this remain 
unclear, and the potential for harm with an EGFR TKI in 
unselected patients cannot be excluded. This study did not col-
lect sufficient samples for translational studies. Rigas et al.58 
conducted a phase II trial in which 250 patients were random-
ized to erlotinib versus placebo after concurrent docetaxel and 
carboplatin and radiotherapy and the median OS was not dif-
ferent (placebo, 26.9 months; erlotinib, 23.6 months).
Because of promising results in head and neck 
cancer60 and a strong radiobiological rationale, there is 
considerable interest in combining cetuximab with concurrent 
chemoradiation in NSCLC. On the basis of results from 
the Radiation Therapy Oncology Group 0324 study61 and 
CALGB-30407,62 a prospective North American randomized 
trial (Radiation Therapy Oncology Group 0617) has been 
tabLE 2.  Recent Phase III Trials of Maintenance Therapy in NSCLC
Reference n Therapy Primary Endpoint PFS OS
Months HR Months HR
Fidias et al.37 309 Immediate docetaxel delayed docetaxel OS 6.5 2.8 0.71 11.9 9.1 0.84
Ciuleanu et al.38 663 Pemetrexed placebo PFS 4.3 2.6 0.50 13.4 10.6 0.79
Belani et al.39 255 Gemcitabine BSC OS 7.4 7.7 1.09 8.0 8.3 0.97
Cappuzzo et al.3 889 Erlotinib placebo PFS 2.83 2.55 0.71 12.0 11.0 0.81
Miller et al.40 768 Erlotinib + bevacizumab Placebo + 
bevacizumab
PFS 4.8 3.7 0.72 15.9 13.9 0.90
Pérol et al.41 464 Erlotinib gemcitabine observation PFS 2.9 3.8 1.9 0.82a 0.55a 11.4 12.1 10.8 0.91a 0.86a
Takeda et al.42 604 Gefitinib placebo OS 4.6 4.3 0.68 13.7 12.9 0.86
Paz-Ares et al.43 539 Pemetrexed placebo PFS 3.9 2.6 0.60b 13.9 11.0 0.78
Zhang et al.44 296 Gefitinib placebo PFS 4.8 2.8 0.42 18.7 16.9 0.83
aVs. observation.
bReassessed at time of final OS.
NSCLC, non–small-cell lung cancer; PFS, progression-free survival; HR, hazard ratio; OS, overall survival; BSC, best supportive care.
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generating further evidence for this principle.63 Patients 
received weekly paclitaxel and carboplatin with concurrent 
thoracic radiation, and initially were randomized to receive 
cetuximab or chemotherapy alone, and to standard-dose or 
high-dose radiation. The high-dose arms were closed at the 
request of the Data and Safety Monitoring Committee, and 
now the results are awaited. In conclusion, there is currently 
no role for EGFR-targeting agents in early- and locally-
advanced NSCLC disease stages outside well-designed 
clinical studies—neither in patients with tumors harboring 
EGFR mutations, nor in those with EGFR wild-type tumors.
thE RoLE oF bIoMaRkERs
First-line EGFR TKI is the preferred therapy for advanced 
NSCLC patients with tumors harboring EGFR mutations, 
and routine molecular testing is recommended. According 
to the new guidelines from the International Association for 
the Study of Lung Cancer, College of American Pathologists, 
and the American Society for Molecular Pathology, perform-
ing molecular testing for EGFR mutations in all patients 
with advanced NSCLC, who have a tumor with adenocarci-
noma or adenocarcinoma components, is recommended.64 
Activating pathways for patients with EGFR wild-type tumors 
are less clear, as they may harbor many molecular abnormali-
ties, including KRAS mutations, anaplastic lymphoma kinase 
(ALK) gene rearrangements, BRAF mutations, and MET gene 
amplifications. Thus, patients with EGFR wild-type tumors 
cannot be considered a unique molecularly-defined group. In 
first-line therapy, there is clear evidence that chemotherapy 
is superior to EGFR TKIs in patients with EGFR wild-type 
tumors,2 whereas the situation is less clear for patients who 
have progressed on chemotherapy. Neither INTEREST, com-
paring gefitinib to docetaxel,65 nor the Tarceva in Treatment 
of Advanced NSCLC trial (TITAN), comparing erlotinib to 
chemotherapy in the second- and third-line setting,66 dem-
onstrated any biomarkers that could predict better or worse 
outcomes with EGFR TKIs. Although, EGFR copy number 
assessed by FISH demonstrated promising predictive asso-
ciations in two second-line placebo-controlled studies,67,68 no 
predictive value of EGFR FISH was seen using the Colorado 
scoring system (FISH+ versus FISH-) when EGFR TKI was 
compared with chemotherapy as second-line therapy in the 
INTEREST study,65 and no predictive association was seen in 
first-line therapy in the IPASS study with EGFR TKI2 or in 
the FLEX31 and BMS-099 studies with cetuximab in combina-
tion with chemotherapy. However, as mentioned above, in the 
randomized phase II study, SWOG-0342 comparing chemo-
therapy with either concomitant or sequential cetuximab as 
first-line therapy, the EGFR FISH-positive group had signifi-
cantly better response and outcome compared with the EGFR 
FISH-negative group.34 Further validation studies are needed, 
which is currently ongoing in the large prospective, random-
ized, phase III study SWOG-0819 (Table 4). A question still 
remains as to whether a more detailed analysis of the EGFR 
copy number per se might identify some patients with EGFR 
wild-type tumors who will benefit from EGFR TKIs. A pro-
teomic classifier (VeriStrat, Biodesix, Boulder, CO) has been 
reported to predict response and outcome in NSCLC patients 
treated with EGFR TKIs.69 In a retrospective analysis from 
BR.21, however, the VeriStrat was predictive for objective 
response, but was not a significant predictor of differential 
survival benefit. The classifier demonstrated a strong prog-
nostic association in the placebo arm.70 Prospective validation 
studies are ongoing with VeriStrat to see if any subgroups of 
advanced NSCLC patients will benefit from this predictive 
assay.
Considerable attention has been devoted to KRAS 
mutations because they have shown a significant negative 
impact on efficacy of EGFR antibody therapy in colorectal 
cancer. EGFR and KRAS mutations are virtually mutually 
exclusive in NSCLC, and tend to track with smoking history. 
However, no different outcome based on KRAS status could 
be shown in either of the two large NSCLC trials studying 
chemotherapy with or without cetuximab (FLEX and BMS-
099).31,32 There is no clear evidence in NSCLC that KRAS 
mutations can be used to exclude patients from receiving 
EGFR TKIs or antibodies, although, several studies have 
demonstrated lack of response to EGFR TKIs in NSCLC 
patients with KRAS mutations.71 The question remains, whether 
all KRAS mutations are created equal?.72 The smoking-
associated KRAS mutations seen in NSCLC are different 
from those in colorectal cancer.73 An interesting perspective 
related to KRAS was to be found in the randomized, phase 
II study comparing dacomitinib to erlotinib by Ramalingam 
et al.54 and further discussed in a companion commentary 
tabLE 3.  Reported and Ongoing Randomized Trials Including EGFR TKI in Early- and Locally-Advanced NSCLC
Author Study
No. of 
Patients
Tumor Response 
Rate (%)
Median PFSa (Months) HR  
(95% CI)
Median OSa (Months) HR  
(95% CI)
Goss et al.56 NCIC CTG BR.19 503 NA Med DFS: 4.2 years vs. NYR  
HR = 1.22 (0.93–1.61, p = 0.15)
Med OS: 5.1 years vs. NYR  
HR = 1.23 (0.94–1.64, p = 0.136)
Kelly et al.57 SWOG-S0023 243 69% vs. 71% 8.3 vs. 11.7 HR = 0.80  
(0.58–1.10, p = 0.17)
23.0 vs. 35.0 HR = 0.633  
(0.44–0.91, p = 0.013)
Rigas et al.58 NCT00153803 243 NA 13.5 vs. 10.4 HR = 0.75  
(0.53–1.08, p = 0.12)
30.4 vs. 25.1, HR = NA  
(p = 0.20)
Richardson et al.59 RADIANT 974 NA NA (ongoing) NA (ongoing)
aEGFR TKI vs. chemotherapy.
EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC, non–small-cell lung cancer; NCIC CTG, National Cancer Institute of Canada Clinical 
Trials Group; med, median; SWOG, Southwest Oncology Group; RADIANT, randomized double-blind trial in adjuvant NSCLC with tarceva; HR, hazard ratio; CI, confidence 
interval; PFS, progression-free survival; OS, overall survival; Med DFS, median disease-free survival; NYR, not yet reached; NA, not available.
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by Oxnard and Janne.74 The phase II study by Ramalingam 
et al.54 demonstrated a significant improvement in PFS with 
dacomitinib in patients with tumors harboring KRAS wild-
type. The strategy of using KRAS wild-type as a means of 
patient enrichment, which is usually used for patients with 
colorectal cancer, has not been clinical practice in lung cancer.
HER2 mutations are rare in NSCLC (2%–5%) and seem 
to be mutually exclusive with other driver oncogene mutations 
(i.e. EGFR, KRAS and ALK alterations),75 and might play an 
important role as a target for the new generation EGFR TKIs, 
or as an acquired resistant mechanism to EGFR inhibitors. 
Ongoing clinical and preclinical studies will shed better light 
on the role of HER2 mutations in the future.
REsIstancE to EGFR InhIbItoRs
definition of acquired resistance
Despite initial dramatic activity of EGFR TKIs in the 
treatment of EGFR mutant cancers, all patients invariably 
acquire resistance, typically within 10 to 14 months.2,7,9 The 
process can be indolent in nature, but can accelerate once the 
EGFR TKI has been stopped.76
The term acquired resistance refers to tumor growth dur-
ing EGFR TKI therapy. Clinical criteria for acquired resistance 
have been developed,77 and are useful in the interpretation of the 
efficacy of treatment strategies aimed at reversing clinical drug 
resistance, for example in some instances, patients can rere-
spond to EGFR TKI therapy after a drug holiday.78–80 Criteria 
for acquired resistance include: (a) treatment with single-agent 
EGFR TKI; (b) confirmed EGFR mutation or a Response 
Evaluation Criteria in Solid Tumors (RECIST)-defined partial 
response or prolonged stable disease (>6 months); (c) RECIST-
defined progression within 30 days of continuous EGFR TKI 
therapy; and (d) no intervening treatment.77
MEchanIsMs oF acquIREd REsIstancE
Several studies have identified mechanisms of drug 
resistance to EGFR TKIs, but to date, mechanisms of acquired 
resistance have been identified only in EGFR mutant cancers. 
It is not known whether the same mechanisms have any role in 
mediating resistance in EGFR wild-type cancers. In addition, 
whether such mechanisms also cause resistance to cytotoxic 
chemotherapy has not been defined.
The most common mechanism of acquired resistance, 
detected in 50% to 60% of patients, is EGFR T790M second-
ary mutation.81–83 EGFR T790M results in increased affinity of 
the receptor for its natural substrate adenosine triphosphate,84 
making it more difficult for reversible EGFR TKIs (gefi-
tinib, erlotinib) to inhibit EGFR kinase activity. One strategy 
to overcome this resistance mutation is to develop covalent 
EGFR inhibitors.11,85–87 Second-generation irreversible inhibi-
tors covalently bind this residue, which allows them to over-
come the increased adenosine triphosphate affinity imparted 
by T790M mutation.84 Several irreversible quinazoline-based 
inhibitors, including afatinib, dacomitinib, and neratinib, are 
effective in gefitinib- or erlotinib-resistant EGFR T790M-
bearing preclinical models.85–87
A second common mechanism of resistance results 
from activation of MET receptor signaling. MET is not the 
immediate or downstream target of EGFR TKIs, but seems to 
provide a bypass signaling pathway, even in the presence of 
EGFR inhibition. MET signaling can be activated as a result 
of MET amplification or by its ligand hepatocyte growth factor 
(HGF).88–91 In both instances, critical downstream signaling 
pathways, including PI3K and ERK1 and 2 signaling, are 
maintained despite EGFR inhibition.88.90 MET amplification 
has been reported in 5% to 20% of drug-resistant cancers, 
whereas HGF accounts for approximately 10% to 20% of 
gefitinib and erlotinib resistance.88–91 Unlike the treatment of 
tabLE 4.  Some Ongoing or Non-Reported Important Phase III Trials with EGFR Inhibitors in Advanced NSCLC
Name of Study Drug Studies Line of Treatment
No. of 
Patients
Primary 
Endpoint
SWOG-0819 Carboplatin/paclitaxel (± bevacizumab) ± cetuximab First-line 1580 OS PFS for  
FISH-positive
SQUIRE Gemcitabine/cisplatin ± necitumumab First-line 1100 OS
NEJ009 Gefitinib vs. gefitinib + carboplatin + pemetrexed 
followed by gefitinib + pemetrexed
First-line 340 OS
IUNO Erlotinib (immediate after ct) vs. erlotinib  
(at progression)
First-line
WJOG 5108L Gefitinib vs. erlotinib Second-line or more 560 PFS
IMPRESS Pemetrexed + cisplatin vs. pemetrexed + cisplatin + 
gefitinib
Second-line after failure of 
gefitinib (in EGFR-mutant 
patients)
250 OS
ARQ-197-006 Tivantinib (arq 197) + erlotinib vs. placebo + 
erlotinib
Second- or third-line (KRAS 
wild-type)
460 OS
LUX-Lung 8 Erlotinib vs. afatinib Second-line (SCC, EGFR wild- 
type)
800 OS
Current s Erlotinib 300 mg vs. 150 mg Second-line (current smokers) 300 PFS
MetLung Erlotinib + ornatuzumab (MetMab) vs. erlotinib Second- or third-line (Met- 
positive)
490 OS
EGFR, epidermal growth factor receptor; NSCLC, non–small-cell lung cancer; OS, overall survival; PFS, progression-free survival; FISH, fluorescence in situ 
hybridization; SWOG, Southwest Oncology Group; WJOG, West Japan Oncology Group.
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EGFR T790M, treatment of drug-resistant cancers harboring 
MET signaling requires a different therapeutic approach, 
such as the combination of EGFR and MET inhibitors.88 This 
strategy has been shown to be effective in preclinical models, 
both in vitro and in vivo.88,89
Less common mechanisms of gefitinib and erlotinib 
resistance include histologic transformation into small-cell 
lung cancer (SCLC) and epithelial to mesenchymal trans-
formation.92,93 The underlying mechanisms leading to these 
events have not yet been elucidated. It is of note that EGFR 
mutant NSCLC tumors that develop SCLC transformation 
seem to respond clinically to chemotherapy typically used in 
SCLC.92
A major challenge in the development of clinical strat-
egies for the treatment of acquired resistance is the lack of 
understanding of the full spectrum of resistance mechanisms. 
Limited studies to date demonstrate that EGFR T790M 
and MET amplification can occur together in drug-resistant 
cancers, either in the same tumor or in different metastatic 
sites.85,86,94 This suggests that therapeutic strategies, such as 
a combination of drugs targeting multiple drug mechanisms 
may be needed. A critical component of studies of drug resis-
tance mechanisms and selection of treatment is the ability to 
rebiopsy drug-resistant tumors, to identify their individual 
mechanisms of resistance.
stRatEGIEs to ovERcoME acquIREd 
REsIstancE
Two strategies to improve outcomes for patients with 
EGFR-mutant NSCLC include delaying development of resis-
tance and treating acquired resistance.
CALGB-30406 evaluated single-agent erlotinib or erlo-
tinib with carboplatin and paclitaxel in a clinically enriched 
population of patients with advanced NSCLC.25 In the sub-
group of patients with EGFR mutation-positive tumors, ORR 
and PFS were not significantly different for patients treated 
with erlotinib alone or erlotinib and chemotherapy. However, 
the combination was associated with more toxicity.25
The irreversible EGFR inhibitor, afatinib, has been 
examined in EGFR mutation-positive gefitinib and erlotinib-
naive patients.14 The ORR (64%) and PFS (14.7 months) are 
similar to those observed with erlotinib in analogous patient 
populations.7,8 An ongoing trial in Japan is examining a beva-
cizumab and erlotinib combination as first-line therapy in 
EGFR mutation-positive NSCLC, based on the subset analy-
sis of EGFR mutation-positive patients from the phase III trial 
of maintenance erlotinib versus erlotinib and bevacizumab.95 
Other treatment strategies include combinations of EGFR 
TKIs, and other signaling inhibitors such as insulin-like 
growth factor receptor 1, c-MET, or HGF. Thus far, none of 
these strategies seem better than single-agent gefitinib or erlo-
tinib as first-line therapy for advanced EGFR mutant NSCLC.
In studies of irreversible quinazoline EGFR inhibitors, 
combinations of EGFR and MET inhibitors, heat shock protein 
90 inhibitors, and mammalian target of rapamycin inhibitors 
alone or in combination with EGFR inhibitors,96–101 the ORR 
has been less than 10% and median PFS only a few months. 
The largest trial was a phase III study of afatinib compared 
with placebo.102 Patients were not selected based on acquired 
resistance criteria, but had to have benefited from prior gefi-
tinib or erlotinib, defined as having received treatment for at 
least 12 weeks. The response rate to afatinib was 7%, and PFS 
was prolonged significantly compared with placebo (3.3 ver-
sus 1.1 months; p < 0.0001), but not OS.102 A similar phase III 
trial of the irreversible EGFR inhibitor dacomitinib compared 
with placebo (National Cancer Institute of Canada Clinical 
Trials Group BR.26) is ongoing.
Afatinib combined with the EGFR-directed antibody 
cetuximab demonstrated remarkable clinical activity in EGFR 
mutation-positive NSCLC patients with acquired resistance.103 
This study was based on preclinical data in a murine model 
of EGFR T790M-mediated NSCLC, where treatment with 
single-agent afatinib or single-agent cetuximab was ineffec-
tive.104 In the phase I and II clinical trial of afatinib or cetux-
imab, the ORR was 36%, far exceeding activity observed in 
prior studies in this patient population.103 Intriguingly, clinical 
responses were observed both in patients with and without 
EGFR T790M..However, one limitation of this approach is 
skin toxicity, imparted by both afatinib and cetuximab.103 This 
study also clinically indicates the continued EGFR depen-
dence in cancers that develop acquired resistance to gefitinib 
or erlotinib. Hence, therapeutic strategies aimed at overcom-
ing resistance should still include an EGFR inhibitor. The acti-
vation of ERBB2 signaling causes resistance to cetuximab, so 
phase III studies combining cetuximab with pan-HER inhibi-
tors should be encouraged.105
Two randomized studies combined erlotinib with MET 
inhibitors. One study with a small molecule inhibitor (tivan-
tinib)106 showed encouraging results in patients with nonsqua-
mous histology (HR = 0.61), and the monoclonal monovalent 
antibody onartuzumab (MetMab, F Hoffmann-La Roche, 
Basel, Switzerland) showed superior outcomes in patients with 
high MET protein expression.107 Both agents are in prospec-
tive phase III studies, although the tivatinib trial (MARQUEE) 
was recently halted because of futility on an interim analysis 
(Press Release from Daiichi Sankyo and ArQuele, October 2, 
2012).The combination of EGFR TKI with a histone deacety-
lation inhibitor may overcome resistance to EGFR TKIs,108 
and a randomized phase II study of erlotinib plus entinostat 
demonstrated some benefit in patients with high E-cadherin 
expression.109
There are several unresolved clinical questions for the 
treatment of EGFR mutation-positive cancers that acquire 
resistance. Progression on any therapy is defined clinically 
by RECIST criteria. Given the sometimes indolent nature 
of EGFR TKI-resistant cancers and the reported flare 
phenomenon after withdrawal of an EGFR inhibitor, patients 
sometimes are treated with EGFR TKIs beyond RECIST-
defined progression. The flare phenomenon refers to a rapid 
(median, 8 days) recurrence of symptoms and symptomatic 
decline (including death), and the phenomenon is observed 
in up to 25% of EGFR-mutant NSCLC patients who stop 
EGFR TKI therapy.110 Thus, many clinicians are treating 
patients beyond RECIST progression. RECIST progression 
is measured from the sum of the smallest lesions, and 
typically, minimal clinically-inconsequential tumor growth 
can be considered progression as most patients achieve 
dramatic initial responses to EGFR TKIs.111 Therefore, even 
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if RECIST progression occurs, many clinicians continue 
therapy in the absence of clinical deterioration or intolerable 
toxicity. However, there are no clinical trial data to provide 
guidance on this approach or on what criteria should be used 
to change treatment.
A second unresolved, yet common, clinical issue is 
the role of chemotherapy at the time of developing acquired 
resistance. No studies have evaluated the outcome of EGFR 
mutation-positive patients treated with chemotherapy after 
EGFR TKI therapy. A global study (IMPRESS) on patients 
with EGFR mutation, comparing a combination of gefitinib 
and chemotherapy, with chemotherapy alone in patients who 
progressed on first-line gefitinib was initiated in 2012.
LIMItatIons oF cuRREnt stRatEGIEs and 
novEL tREatMEnt appRoachEs
Continued efforts are needed to improve EGFR-targeted 
treatment and to develop additional agents, including muta-
tion-selective EGFR TKIs.112 Furthermore, clinical trials 
need to combine agents that can target multiple resistance 
mechanisms concurrently.113 A clinical trial is underway com-
bining the irreversible EGFR inhibitor dacomitinib with the 
Echinoderm microtubule-associated protein-like 4-ALK- and 
MET inhibitor, crizotinib (this combination could be partic-
ularly beneficial for the very few patients with tumors har-
boring both EGFR- and ALK-mutations). This trial, still in 
the early stages, has the potential to be effective for patients 
who have developed the most common mechanisms of drug 
resistance (EGFR T790M and activated MET signaling). It 
is likely that the optimal therapy for EGFR mutation-positive 
NSCLC patients may involve a combination of multiple drugs 
to achieve durable long-term outcomes.
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